ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 2553
Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study
Abstract Number: 2554
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort
Abstract Number: 2555
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Abstract Number: 2556
Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician’s Diagnosic Confidence? Results from the DESIR Cohort
Abstract Number: 2557
Are We over-Treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort
Abstract Number: 2558
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
Abstract Number: 2559
Vitamin D insufficiency  and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders
Abstract Number: 2560
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2561
Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis
Abstract Number: 2562
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis  and ankylosing spondylitis; results from Turkbio Registry
Abstract Number: 2563
The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of TNF-α-Blockade
Abstract Number: 2564
Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis
Abstract Number: 2565
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Abstract Number: 2566
Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis
Abstract Number: 2567
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Abstract Number: 2568
Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Abstract Number: 2569
Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
Abstract Number: 2570
Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis
Abstract Number: 2571
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Abstract Number: 2572
Recognition of  Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients
Abstract Number: 2573
Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Abstract Number: 2574
Do Patients with Axial Spondyloarthritis (AxSpA) Perform Enough Physical Activity? a Cross-Sectional Study of 207 Patients
Abstract Number: 2575
Validation of the RAPID-3 Questionnaire in a Cohort of Patients with Axial Spondyloarthritis
Abstract Number: 2576
Diffusing Weight Magnetic Resonance Imaging May Suggest the Treatment Strategy in Ankylosing Spondylitis
Abstract Number: 2577
The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2578
Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort.
Abstract Number: 2579
How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? – an Analysis in the DESIR Cohort
Abstract Number: 2580
A Comparison of Baseline Characteristics and Real-Life Effectiveness of Anti-TNF Therapy in Non-Radiographic Axial Spondyloarthritis Versus Ankylosing Spondylitis – a Single Center Cohort Study
Abstract Number: 2581
Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint
Abstract Number: 2582
Serum Levels of Bone Morphogenetic Protein-7 and Sclerostin Are Elevated in Ankylosing Spondylitis, but Not Linked with Structural Damage
Abstract Number: 2583
Unexpected High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis
Abstract Number: 2584
Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis
Abstract Number: 2585
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Abstract Number: 2586
Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of Sacroiliitis on Magnetic Resonance Imaging (MRI)? Results from the Esperanza Cohort
Abstract Number: 2587
Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis
Abstract Number: 2588
Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of HLA-B27? Results from the Esperanza Cohort
Abstract Number: 2589
EULAR Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice
Abstract Number: 2590
Comparison of Radiographic Damage Score in Ankylosing Spondylitis According to Tumor Necrosis Factor Inhibitor: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) Data
Abstract Number: 2591
Effects of Self-Management Model on the Disease-Related Knowledge, Joint Function and Quality of Life in Patients with Ankylosing Spondylitis
Abstract Number: 2592
Assessment of Spondyloarthritis International Society Endorsed Recommendations for Early Referral of Patients Suspected for Axial Spondyloarthritis
Abstract Number: 2593
Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort
Abstract Number: 2594
Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment
Abstract Number: 2595
Using Iphone Compass Application for the Assessment of Cervical Rotation in Patients with Ankylosing Spondylitis
Abstract Number: 2596
Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort
Abstract Number: 2597
Impact of Repeating Imaging of the Sacro-Iliac Joints over One Year on the Classification According the ASAS Axial Spa Criteria of Patients
Abstract Number: 2598
Disease Characteristics Associated with the Presence of Dactylitis in Patients with EARLY Spondyloarthritis: Results from Esperenza Cohort
Abstract Number: 2599
Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF
Abstract Number: 2600
Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study
Abstract Number: 2601
Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab
Abstract Number: 2602
Prevalence of Subclinical Atherosclerosis in Patients with Spondyloarthritis without Clinically Evident Cardiovascular Disease Using Carotid Intima-Media Thickness
Abstract Number: 2603
Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study
Abstract Number: 2604
Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis :      the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort
Abstract Number: 2605
Profiling Ankylosing Spondylitis Patients Likely to Respond to NSAID Treatment
Abstract Number: 2606
How to Classify Spondyloarthritis after a Two Year Follow up? Results from the French Recent onset spondyloarthritis Cohort
Abstract Number: 2607
Fatigue in Ankylosing Spondylitis: A Multivariable Analysis Implicates Inflammation As the Key Determinant of Disability
Abstract Number: 2608
Do You Assess Gastro-Intestinal Auto-Antibodies and Symptoms in Patients with Spondyloarthritis?
Abstract Number: 2609
Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents
Abstract Number: 2610
The Role of IL-20 in the Pathogenesis of Ankylosing Spondylitis with Peripheral Joint Involvement
Abstract Number: 2611
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and  ankylosing  Spondylitis; Results from Turkbio Registry
Abstract Number: 2612
Different Performance of the Major Disease Activity Measures ASDAS and Basdai in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti-Inflammatory Agents – Results from a Prospective Study
Abstract Number: 2613
Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
Abstract Number: 2614
Reliability of Electronic Patient Self-Assessment of Swollen and Tender Joints in Psoriatic Arthritis: A Comparison Study with B-Mode Ultrasonography, Physician and Nurse Assessments
Abstract Number: 2615
Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis
Abstract Number: 2616
Comparison of Characteristics of Ankylosing Spondylitis in Association with Familial Mediterranean Fever with Those of Typical Ankylosing Spondylitis
Abstract Number: 2617
No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Abstract Number: 2618
Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology